Black patients with scleroderma experience faster disease progression, higher prevalence of diffuse skin involvement, and higher mortality than Asian or white patients, a study reports. In addition, Asian patients were found to have earlier disease onset, faster disease course, and more lung involvement and pulmonary hypertension…
News
Treatment with Ofev (nintedanib) slows the rate of lung function decline in people with autoimmune-related interstitial lung diseases (ILDs), including scleroderma, a new analysis shows. Those are the results of the global Phase 3 INBUILD study (NCT02999178), which evaluated the therapeutic benefits of Ofev in people with…
People with scleroderma who were younger and had thicker skin at the onset of their disease experience an increased risk of heart muscle (myocardial) inflammation, a new study suggests. The research, “Clinical and laboratory predictions of myocardial inflammation as detected by cardiac magnetic resonance imaging in patients with…
Treatment with Letairis (ambrisentan) failed to significantly reduce pulmonary blood pressure at rest and during exercise compared with a placebo in people with scleroderma and mild pulmonary hypertension (PH), a Phase 2 trial showed. However, the therapy improved cardiac function and blood flow in the lungs —…
Skin Lesions Develop Soon After Onset of Raynaud’s Phenomenon, 10-year Follow-up Study Reports
Most people with scleroderma develop skin lesions within one year after the onset of Raynaud’s phenomenon (RP), a condition in which the fingers and toes feel numb, prickly, and frigid in response to cold temperatures or stress, a 10-year follow-up study reports. The findings also showed a continuous…
Digital Ulcers Strongly Affect Pain and Daily Life in Scleroderma Patients, Spanish Study Finds
Digital ulcers (DUs) aggravate hand disability, limit daily activities, and affect work productivity in people with scleroderma, a real-world study from Spain reports. Patients with DUs had more pain, a higher incidence of Raynaud’s phenomenon, and reported having…
Real-world clinical data support the use of Opsumit (macitentan) to treat people with pulmonary arterial hypertension (PAH) due to scleroderma (PAH-SSc). The findings revealed similar safety results and comparable therapeutic efficacy in people with PAH-SSc as seen in patients with idiopathic or hereditary…
A recently discovered variant of the IFNL3 gene increases the risk of pulmonary fibrosis (PF) in people with scleroderma, a study reveals. In contrast, no such link was found between this variant and worsened skin fibrosis in these patients. Findings also revealed markedly increased serum levels of…
People with systemic sclerosis (SSc) show a wide range of eye complications, with dry eye disease, eyelid skin alterations, and retinal abnormalities as the most common, a Hungarian study shows. The variety of eye complications found in these patients reflect the heterogeneity, or diversity, of SSc —…
People with scleroderma can develop autoimmune diseases like neuromyelitis optica (NMO), a condition that affects the nervous system — especially the nerves of the eye and spinal cord, a case report suggests. Correctly diagnosing a co-occurring autoimmune disease help to ensure that scleroderma patients receive proper care early,…
Recent Posts
- New scleroderma survey seeks patient input to guide future research
- Scleroderma added to NIH project targeting autoimmune diseases
- Off-the-shelf cell therapy shows early promise as scleroderma treatment
- Trial to test scleroderma treatments at earliest stages of disease
- Off-label JAK inhibitors may stabilize lung function in systemic sclerosis
- Distinct symptom pattern found for triple-negative scleroderma patients
- Plant-based nanoparticle therapy eases skin thickening in SSc: Study
- Specialized MRI scans may catch early lung damage in scleroderma
- Spotlighting ‘Beacons of Hope’ for this year’s Scleroderma Awareness Month
- Fewer capillaries in hands may contribute to scleroderma bone loss